Shore Capital Reaffirms “Hold” Rating for AstraZeneca (AZN)

AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by research analysts at Shore Capital in a research report issued to clients and investors on Friday.

A number of other research analysts also recently commented on AZN. Societe Generale reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Thursday, September 21st. Sanford C. Bernstein set a GBX 5,780 ($78.38) price target on AstraZeneca and gave the company a “buy” rating in a research note on Monday, September 25th. Barclays reaffirmed an “overweight” rating and issued a GBX 6,300 ($85.44) price target on shares of AstraZeneca in a research note on Monday, September 25th. BNP Paribas set a GBX 5,800 ($78.65) price target on AstraZeneca and gave the company a “buy” rating in a research note on Monday, September 25th. Finally, Deutsche Bank reaffirmed a “buy” rating and issued a GBX 5,600 ($75.94) price target on shares of AstraZeneca in a research note on Thursday, October 5th. Four equities research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the stock. AstraZeneca has a consensus rating of “Hold” and an average target price of GBX 5,219 ($70.78).

AstraZeneca (AZN) traded up GBX 62.50 ($0.85) during mid-day trading on Friday, reaching GBX 5,043 ($68.39). The company had a trading volume of 3,019,909 shares, compared to its average volume of 1,610,000. The firm has a market capitalization of $63,860.00 and a P/E ratio of 2,508.96. AstraZeneca has a fifty-two week low of GBX 4,136.50 ($56.10) and a fifty-two week high of GBX 5,520 ($74.86).

ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/01/21/shore-capital-reaffirms-hold-rating-for-astrazeneca-azn.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply